HRTX — Heron Therapeutics, Inc.

Summary of Heron Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenues: Approximately $155 million for the full year 2025, exceeding guidance of $9 million to $13 million for adjusted EBITDA, which stood at $14.7 million.
• Gross Margin: Approximately 73%, reflecting improved cost discipline and product mix.
• Q4 Performance: Acute Care net sales reached $16.3 million, a 33% increase from Q3, driven by ZYNRELEF ($12.5 million, up 48% YoY) and APONVIE ($3.8 million, up 97% YoY).
• Oncology Franchise: Generated over $105 million in net revenue, a 7.8% decline YoY, primarily due to the planned wind-down of SUSTOL.

2. Strategic Updates and Business Highlights

• Successful Financing: Completion of financing has removed a significant overhang, allowing focus on commercial execution and product expansion.
• Acute Care Initiatives: Launched the CrossLink IGNITE program to enhance distributor engagement and introduced a vial access needle (VAN) to streamline hospital use of ZYNRELEF.
• Regulatory Developments: A new permanent J-Code for ZYNRELEF was implemented, improving reimbursement clarity.
• Sales Team Expansion: A dedicated sales team for APONVIE was established, contributing to its strong growth and inclusion in the Fifth Consensus Guidelines for PONV management.

3. Forward Guidance and Outlook

• 2026 Guidance: Projected net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million, indicating continued profitability amidst planned commercial investments.
• Commercial Strategy: Plans to expand the commercial team in key markets to drive growth, with an emphasis on areas with existing traction and favorable dynamics.

4. Bad News, Challenges, or Points of Concern

• Oncology Decline: The oncology franchise saw a decline primarily due to SUSTOL's wind-down, raising concerns about the stability of this revenue stream.
• Competitive Pressures: Increased competition in the oncology space, particularly for CINVANTI, poses risks to maintaining revenue levels.
• NOPAIN Act Awareness: Initial slow adoption and understanding of the NOPAIN Act among providers may hinder the expected benefits, although awareness is improving.

5. Notable Q&A Insights

• CINVANTI Outlook: Expected to see unit volume growth but potential price erosion, leading to relatively flat sales throughout 2026.
• NOPAIN Act: Management believes it will be a strong tailwind, with ongoing education efforts to enhance provider awareness.
• VAN Rollout: The rollout was smooth, and learnings will inform the prefilled syringe launch strategy, which is expected to follow a similar approach.
• Litigation Update: Confidence in the CINVANTI litigation outcome, with a decision anticipated before the 30-month stay.
• Guideline Impact on APONVIE: Inclusion in the Fifth Consensus Guidelines is expected to significantly enhance adoption, with a timeframe of 6-9 months for material effects.

Overall, Heron Therapeutics demonstrated strong financial performance in 2025, with strategic initiatives positioning the company for growth in 2026, despite facing challenges in the oncology segment and the need for increased awareness of new reimbursement frameworks.